Nautilus Biotechnology (NASDAQ:NAUT) just reported results for the first quarter of 2024.
- Nautilus Biotechnology reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -16 cents.
- The company did not report any revenue for the quarter.